Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA v. Brown & Williamson Tobacco Corp.

This article was originally published in The Gray Sheet

Executive Summary

Supreme Court rules by a five-to-four margin March 21 that the Food Drug and Cosmetic Act does not authorize FDA to regulate tobacco products as medical devices. The FDCA allows FDA to regulate products that are unsafe for obtaining therapeutic benefit; but if tobacco products cannot be used safely for any therapeutic purpose, they fall outside of FDCA's regulatory scheme, the court concluded. Congressional action would be needed to grant FDA the explicit authority to regulate tobacco products. FDA's "nonsensical attempts" to regulate tobacco products as medical devices "was a colossal mistake from the beginning," Medical Device Manufacturers Association Executive Director Stephen Northrup comments in a same day release. It "would have set back the FDA's efforts to build a more reasonable regulatory structure for our industry's products at a time when the promise of medical technology has never been greater"

You may also be interested in...



OTC Marketing Awards Just Two Weeks Away

This year's OTC Marketing Awards is celebrating innovation and creativity in the British consumer healthcare industry.

US FDA Pharmaceutical Quality Office Lauds Continuous Manufacturing Approvals

The FDA’s OPQ touts approval of sixth and seventh continuously manufactured drugs and quicker delivery of inspection results in latest annual report.

Warning Letter Roundup & Recap – 19 February 2020

No device-related warning letters were released by the US FDA the week of 19 February.

UsernamePublicRestriction

Register

MT013152

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel